Nutella celebrates milestone with limited-edition Cronuts
SOMERSET, N.J. — Nutella, a brand from Ferrero U.S.A., on Monday celebrated its 50th anniversary by teaming up with Dominique Ansel, chef and owner of Dominique Ansel Bakery in New York City and the originator of the Cronut — a donut-croissant pastry for the uninitiated — to create limited-edition Cronut holes made with Nutella. The special treats will be available today only in New York City, with Ansel distributing them throughout the event, which took place at the Broadway Pedestrian Plaza.
"I’m thrilled to be partnering with Nutella to help celebrate its 50th anniversary. I have fond memories of enjoying Nutella at breakfast as a little boy in France and have always been an enthusiast. Having the opportunity to incorporate Nutella into bite-size versions of the Cronut has been a real joy, and I look forward to seeing fans enjoy this special treat," Ansel said.
The celebration also marks the debut of a new Nutella food truck that will "Spread the Happy" throughout 16 U.S. cities by offering complimentary samples of Nutella, games and more.
"The passion our fans have for the Nutella brand is incredible. They have a deep personal connection to the hazelnut spread and are constantly engaging with us via social media. We’re so excited to celebrate alongside them at this anniversary event and kickoff our national tour, which will spread the happiness one finds in a jar of Nutella throughout the country," said Eric Berger, senior brand manager for Nutella at Ferrero U.S.A. "We look forward to continuing to promote their love and passion for Nutella and celebrating 50 more years!"
L’Oréal unveils ‘game-changing digital experience’
PARIS — L’Oréal Paris is bringing the personalized service of a department store to the mass market with its latest in beauty digital innovation — “Makeup Genius.”
Based on the insight that beauty is one of the most “Googled” topics in the world — with about 4 billion searches a year — the group’s innovation incubator decided to respond to the needs expressed by consumers by offering greater customization and interaction with their brand.
“By combining our knowledge of consumers and the science of colors with technologies for monitoring facial expressions, we have been able to calculate the best possible algorithm capable of producing an extremely realistic colur-rendering in real time using just an iPhone camera,” stated Guive Balooch, director of the Connected Beauty Incubator for L’Oréal Research & Innovation. This innovation will enable L’Oréal Paris to offer all women an unprecedented beauty “e-routine.”
The world market leader in beauty, L’Oréal Paris aims to be a pioneer in tools offering consumers a personalized experience. L’Oréal’s Makeup Genius enables consumers to test makeup products using their mobile phone or tablet as a virtual mirror and play with new looks in real time.
Unlike other virtual makeup apps that render colors onto a pre-uploaded static image, L’Oréal Paris uses facial mapping technology to transform your iPhone or iPad’s front-facing camera into a virtual mirror where you can try on L’Oreal Paris products. Facial expressions are detected and reproduced, allowing for a result that looks like you actually applied makeup. Makeup Genius captures 64 facial data points and up to 100 expressions.
Consumers can now test makeup products, a new makeup look or scan a bar code at the point of sale and instantly experience the most premium and innovative Before & After service.
“We believe that one of the major trends to come concerns the virtual reality experience, which will offer consumers a new and effective way of trying products, learning how to use them and personalize them, with unparalleled results for the consumer,” said Cyril Chapuy, president of L’Oréal Paris International.
Makeup Genius will be launched in France, the United States and China in May, then in other countries where the brand is present.
AstraZeneca rejects Pfizer’s final bid of $118 billion
NEW YORK — Pfizer on Sunday made a final offer valued at $118 billion for AstraZeneca. AstraZeneca, in turn, rejected the bid Monday morning.
"Even assuming that other key aspects of any proposal had been satisfactory, … the price at which the board of AstraZeneca would be prepared to provide a recommendation would have to be more than 10% above the level contained in Pfizer’s [latest] proposal," stated Leif Johansson, AstraZeneca chairman. "The final proposal is a minor improvement that continues to fall short of the board’s view of value and has been rejected.”
According to Pfizer’s revised offer, AstraZeneca shareholders would receive, for each AstraZeneca share, 1.747 shares in the combined entity and 2,476 pence in cash, representing an indicative value of £55.00 per share (or approximately $92.60 per share). The revised offer represents an increase of approximately 15% over the value of Pfizer’s May 2 proposal.
AstraZeneca’s rejection may represent the end of the discussion. "Pfizer will not make a hostile offer directly to AstraZeneca shareholders and will only announce an offer with the recommendation of the AstraZeneca board," Pfizer stated Sunday.
“We believe our proposal is compelling for AstraZeneca’s shareholders and that a Pfizer-AstraZeneca combination is in the best interests of all stakeholders," said Ian Read, Pfizer chairman and CEO. "We have tried repeatedly to engage in a constructive process with AstraZeneca to explore a combination of our two companies. Following a conversation with AstraZeneca earlier, … we do not believe that the AstraZeneca board is currently prepared to recommend a deal at a reasonable price. We remain ready to engage in a meaningful dialogue, but time for constructive engagement is running out. We have said from the beginning that we will remain disciplined in the price we are willing to pay, and we will not depart from that guiding principle. We believe that our proposal represents compelling and full value for AstraZeneca and that other issues that have been raised by AstraZeneca do not represent material difficulties.”
Sunday’s offer represents the fourth proposal Pfizer has made.